No Data
Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis
Truist Financial Sticks to Their Buy Rating for Mersana Therapeutics (MRSN)
Earnings Call Summary | Mersana Therapeutics(MRSN.US) Q1 2024 Earnings Conference
The following is a summary of the Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript:Financial Performance:Mersana reported a healthy balance sheet for Q1 2024, with $183.1 million in
Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript